EGFR and neoplasm: A similar effect of EphA2 on proliferation was also reported by us [32] as well as by Amato et al. which furthermore demonstrated that targeting EphA2 in KRAS or EGFR mutant NSCLC impaired tumor growth in mice and facilitated apoptotic response by decreasing S6K1-mediated phosphorylation of BAD [27].